In a strategic move to enhance healthcare access, Pakistan and Russia have launched pharmaceutical joint ventures aimed at importing and eventually manufacturing insulin locally. The initiative was formalized during a high-level meeting chaired by Special Assistant to the Prime Minister Haroon Akhtar Khan, with participation from Russian government representative Denis Nazarov, and officials from the Ministry of Industries, National Health Services, and DRAP2.
Insulin Imports and Registration
Pakistan’s Genetics Pharmaceuticals received DRAP approval to import insulin from Russian firm Zavod Medisintez on May 5, 2025. The move is expected to benefit millions of diabetic patients, given Pakistan’s status as a major insulin consumer.
Local Manufacturing Plans
Efforts are underway to initiate domestic production of insulin, with a joint protocol between Pakistani and Russian manufacturers expected soon. This aligns with Prime Minister Shehbaz Sharif’s vision for healthcare self-reliance3.
Pricing and Regulatory Oversight
Genetics Pharmaceuticals has applied for a maximum retail price (MRP) adjustment based on inflation, as permitted under the Drug Pricing Policy 2018. However, concerns have been raised that the proposed MRP may exceed prices of insulin from European competitors like Novo Nordisk.
Leadership Commentary
Haroon Akhtar Khan emphasized that the JV marks a milestone in bilateral relations, and directed stakeholders to develop a comprehensive proposal for cabinet review. The initiative is expected to strengthen Pakistan’s pharma sector and ensure consistent insulin supply.
+ There are no comments
Add yours